IBIO · Ibio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $0 | $100.0K | $200.0K | $0 | $0 | - | - | $50.0K | $0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.25M | $4.28M | $3.55M | $1.88M | $1.91M | $1.30M | $1.53M | $904.0K | $1.61M | $2.78M |
| SG&A | $5.11M | $5.17M | $2.50M | $2.74M | $2.97M | $2.80M | $2.96M | $2.72M | $3.55M | $7.79M |
| Total Operating Expenses | $8.37M | $9.45M | $6.05M | $4.62M | $4.88M | $4.11M | $4.50M | $3.63M | $5.15M | $10.57M |
| D&A | - | - | $123.0K | - | - | $120.0K | - | - | $165.0K | - |
| Operating Income | ($8.37M) | ($9.45M) | ($5.95M) | ($4.42M) | ($4.88M) | ($4.11M) | ($4.50M) | ($3.63M) | ($5.10M) | ($10.57M) |
| Interest Expense | $22.0K | $41.0K | $36.0K | $34.0K | $52.0K | $26.0K | $34.0K | $52.0K | $26.0K | $31.0K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($7.73M) | ($8.99M) | ($5.72M) | ($8.21M) | ($3.17M) | ($3.99M) | ($8.21M) | ($3.17M) | ($5.07M) | ($33.55M) |
| EPS - Basic | ($0.06) | ($0.09) | ($0.11) | ($0.48) | ($0.49) | ($0.46) | ($4.42) | ($0.85) | ($4.80) | ($68.40) |
| EPS - Diluted | ($0.06) | ($0.09) | ($0.11) | ($0.48) | ($0.49) | ($0.46) | ($4.42) | ($0.85) | ($4.80) | ($68.40) |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $47.63M | $28.67M | $28.11M | $8.58M | $4.96M | $11.04M | $14.21M | $5.30M | $1.46M | $4.30M |
| Accounts Receivable | - | - | $65.0K | - | - | - | - | - | $0 | $970.0K |
| Inventory | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Accounts Payable | $3.04M | $2.65M | $2.82M | $2.19M | $1.48M | $855.0K | $358.0K | $1.23M | $1.91M | $1.85M |
| Current Assets | $77.25M | $53.37M | $50.77M | $9.72M | $6.06M | $11.71M | $15.67M | $36.14M | $23.02M | $26.26M |
| Total Assets | $85.83M | $64.39M | $64.16M | $23.18M | $19.10M | $24.52M | $28.73M | $50.15M | $37.68M | $41.21M |
| Current Liabilities | $6.50M | $5.90M | $6.05M | $6.11M | $5.40M | $3.47M | $3.84M | $21.43M | $20.71M | $21.58M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $8.30M | $7.83M | $8.12M | $8.30M | $7.72M | $6.76M | $7.41M | $25.29M | $24.47M | $25.83M |
| Stockholders' Equity | $77.54M | $56.56M | $56.04M | $14.88M | $11.38M | $17.75M | $21.32M | $24.86M | $13.21M | $15.38M |
| Retained Earnings | ($354.67M) | ($346.94M) | ($337.94M) | ($332.22M) | ($327.06M) | ($317.84M) | ($313.85M) | ($306.07M) | ($294.69M) | ($288.94M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($5.67M) | - | - | ($3.71M) | - | - | ($5.34M) | - |
| Investing Cash Flow | - | - | ($21.49M) | - | - | $713.0K | - | - | $50.0K | - |
| Financing Cash Flow | - | - | $46.70M | - | - | ($162.0K) | - | - | $2.47M | - |
| CapEx | - | - | $0 | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | ($5.67M) | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -5951.0% | -2209.5% | - | - | - | - | -10206.0% | - |
| EBITDA margin | - | - | -5828.0% | - | - | - | - | - | -9876.0% | - |
| Net margin | - | - | -5720.0% | -4105.5% | - | - | - | - | -10148.0% | - |
| Free cash flow margin | - | - | -5665.0% | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.99 | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 3550.0% | 938.5% | - | - | - | - | 3212.0% | - |
| SG&A / Revenue | - | - | 2501.0% | 1371.0% | - | - | - | - | 7094.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.0% | -14.0% | -8.9% | -35.4% | -16.6% | -16.3% | -28.6% | -6.3% | -13.5% | -81.4% |
| Return on equity | -10.0% | -15.9% | -10.2% | -55.2% | -27.9% | -22.5% | -38.5% | -12.8% | -38.4% | -218.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 11.88 | 9.04 | 8.39 | 1.59 | 1.12 | 3.37 | 4.08 | 1.69 | 1.11 | 1.22 |
| Quick ratio | 11.88 | 9.04 | 8.39 | 1.59 | 1.12 | 3.37 | 4.08 | 1.69 | 1.11 | 1.22 |
| Cash ratio | 7.32 | 4.86 | 4.65 | 1.41 | 0.92 | 3.18 | 3.70 | 0.25 | 0.07 | 0.20 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -380.2x | -230.4x | -165.3x | -130.0x | -93.8x | -157.9x | -132.2x | -69.7x | -196.3x | -341.1x |
| Equity multiplier | 1.11 | 1.14 | 1.14 | 1.56 | 1.68 | 1.38 | 1.35 | 2.02 | 2.85 | 2.68 |
| Liabilities / Assets | 0.10 | 0.12 | 0.13 | 0.36 | 0.40 | 0.28 | 0.26 | 0.50 | 0.65 | 0.63 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | - | - | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | 237d | - | - | - | - | - | 0d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.9x | 3.4x | 0.8x | 0.5x | 3.5x | 1.1x | 0.2x | 0.6x | 10.9x | 7.8x |
| P / S | - | - | 439.7x | 34.7x | - | - | - | - | 2876.3x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -100.0% | - | - | - | -100.0% | - | - | - | -100.0% |
| Revenue CAGR (3y) | - | - | - | 6.0% | - | - | - | - | -50.4% | - |
| Revenue CAGR (5y) | - | - | -24.6% | -8.6% | - | - | - | - | -16.3% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -71.4% | -113.7% | -44.9% | 1.7% | -34.6% | 19.5% | 57.5% | 41.2% | 33.2% | 9.2% |
| Net income growth (YoY) | -143.7% | -9.5% | -43.4% | 0.0% | 0.0% | 21.4% | 75.5% | 56.5% | 72.0% | -181.5% |
| EPS growth (YoY) | 87.8% | 81.3% | 76.1% | 89.1% | 42.4% | 90.4% | 93.5% | -54.5% | -366.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 581.3% | 280.1% | 215.6% | -30.2% | -54.2% | 34.4% | 38.6% | 43.0% | -72.7% | -75.8% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing iBio against the 5 most active filers in the same SIC group.